J Pediatr Intensive Care 2020; 09(03): 225-232
DOI: 10.1055/s-0040-1709994
Rapid Communication
Georg Thieme Verlag KG Stuttgart · New York

Chitin Analog AVR-25 Prevents Experimental Bronchopulmonary Dysplasia

Pragnya Das**
1  Department of Pediatrics, Division of Neonatology, Drexel University, Philadelphia, Pennsylvania, United States
,
Suchismita Acharya**
2  Acceleration Laboratory, University of North Texas Health Science Center, Fort Worth, Texas, United States
3  AyuVis Research Inc, Fort Worth, Texas, United States
,
Dilip Shah*
1  Department of Pediatrics, Division of Neonatology, Drexel University, Philadelphia, Pennsylvania, United States
,
Beamon Agarwal
4  GenomeRxUS, Secane, Pennsylvania, United States
,
Varsha Prahaladan*
1  Department of Pediatrics, Division of Neonatology, Drexel University, Philadelphia, Pennsylvania, United States
,
Vineet Bhandari*
1  Department of Pediatrics, Division of Neonatology, Drexel University, Philadelphia, Pennsylvania, United States
› Author Affiliations
Funding This work was partly supported by a research contract grant received from AyuVis Research Inc.
Further Information

Publication History

13 February 2020

27 March 2020

Publication Date:
08 May 2020 (online)

Abstract

Infants born extremely preterm are at a high risk of developing bronchopulmonary dysplasia (BPD) which is characterized by large, simplified alveoli, increased inflammation, disrupted and dysregulated vasculogenesis, decreased cell proliferation, and increased cell death in the lungs. Due to lack of specific drug treatments to combat this condition, BPD and its long-term complications have taken a significant toll of healthcare resources. AVR-25, a novel immune modulator experimental compound, was able to partially recover the pulmonary phenotype in the hyperoxia-induced experimental mouse model of BPD. We anticipate that AVR-25 will have therapeutic potential for managing human BPD.

* Current affiliation: Cooper Health University and Hospital, Suite 206, 401 Haddon Avenue, Education and Research Building, Camden, NJ 08103, USA.


** These authors contributed equally to this article.


Authors' Contributions

P.D., S.A., B.A., and V.B. conceptualized and designed the study, drafted the initial manuscript, and submitted as approved; P.D., S.A., D.S., B.A., and V.P. performed the initial experiments. All the authors approved the final manuscript.